While the broad activity of cerdulatinib in DLBCL cell lines may be ascribed to mechanisms beyond SYK and JAK inhibition (Table 1), the data presented herein with DLBCL cell lines and primary tumors are at least consistent with the hypothesis that SYK and JAK inhibition contributes to the antitumor activities of the drug. Here, SYK is linked to diffuse large B-cell lymphoma.